Stock Events

Stock Events

NeuBase Therapeutics 

$0.38
5
-$0.01-3.2% Friday 22:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

9MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-2.1
-1.44
-0.77
-0.11
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
0Revenue
-33.78MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NBSE. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is focused on developing gene-based medicines, directly competing with NeuBase's gene editing approach.
Editas Medicine
EDIT
Mkt Cap261.32M
Editas Medicine works on genome editing technologies, similar to NeuBase's platform, making them direct competitors in the gene therapy space.
Intellia Therapeutics
NTLA
Mkt Cap1.55B
Intellia Therapeutics is a leading developer of CRISPR gene editing treatments, competing in the same gene therapy market as NeuBase.
Beam Therapeutics
BEAM
Mkt Cap2.51B
Beam Therapeutics uses base editing, a form of gene editing, positioning it as a competitor in the precision genetic medicine field alongside NeuBase.
Sangamo Therapeutics
SGMO
Mkt Cap124.32M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, competing with NeuBase in the development of genetic treatments.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.29B
Alnylam Pharmaceuticals is a leader in RNAi (RNA interference) therapeutics, competing with NeuBase's approach to gene silencing and editing.
Ionis Pharmaceuticals
IONS
Mkt Cap12.35B
Ionis Pharmaceuticals focuses on RNA-targeted drug discovery and development, making it a competitor in the genetic medicine space.
Precision Biosciences
DTIL
Mkt Cap143.91M
Precision BioSciences utilizes its ARCUS genome editing platform to develop genetic treatments, competing with NeuBase's therapeutic approaches.
Voyager Therapeutics
VYGR
Mkt Cap236.01M
Voyager Therapeutics specializes in the development of gene therapies for neurodegenerative diseases, representing competition in the broader gene therapy field.

About

Health Technology
Biotechnology
Pharmaceuticals: Major
Manufacturing
Pharmaceutical Preparation Manufacturing
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Show more...
CEO
Dietrich Stephan
Employees
37
Country
United States
ISIN
US64132K1025
WKN
000A2PNYF

Listings

0 Comments

Share your thoughts

FAQ

What is NeuBase Therapeutics stock price today?▼
The current price of NBSE is $0.38 USD — it has decreased by -3.2% in the past 24 hours. Watch NeuBase Therapeutics stock price performance more closely on the chart.
What is NeuBase Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange NeuBase Therapeutics stocks are traded under the ticker NBSE.
What is NeuBase Therapeutics revenue for the last year?▼
NeuBase Therapeutics revenue for the last year amounts to 0 USD.
What is NeuBase Therapeutics net income for the last year?▼
NBSE net income for the last year is -33.78M USD.
How many employees does NeuBase Therapeutics have?▼
As of April 12, 2026, the company has 37 employees.
In which sector is NeuBase Therapeutics located?▼
NeuBase Therapeutics operates in the Technology sector.
When did NeuBase Therapeutics complete a stock split?▼
The last stock split for NeuBase Therapeutics was on June 15, 2023 with a ratio of 1:20.
Where is NeuBase Therapeutics headquartered?▼
NeuBase Therapeutics is headquartered in Pittsburgh, United States.